申请人:Nakatani Kazuhiko
公开号:US20070037841A1
公开(公告)日:2007-02-15
An inhibitor contains naphthyridine dimer, a naphthyridine-azaquinolone hybrid, a trinaphthyridine-azaquinolone hybrid, or a trinaphthyridine-azaquinolone hybrid derivative. In order to inhibit binding of 100 nM of RRE to 100 nM of Rev protein, for example, an inhibitor containing naphthyridine dimer is used at a molarity of 1.2 μM to 12 μM, an inhibitor containing the naphthyridine-azaquinolone hybrid is used at a molarity of 2 μM to 20 μM, or an inhibitor containing the trinaphthyridine-azaquinolone hybrid derivative is used at a molarity of 200 nM to 2 μM. This makes it possible to effectively inhibit binding of RRE to Rev protein.
一种抑制剂包含萘啶二聚体、萘啶-氮杂喹啉杂交物、三萘啶-氮杂喹啉杂交物或三萘啶-氮杂喹啉杂交物衍生物。例如,为了抑制100 nM的RRE与100 nM的Rev蛋白质的结合,使用含有萘啶二聚体的抑制剂浓度为1.2 μM至12 μM,使用含有萘啶-氮杂喹啉杂交物的抑制剂浓度为2 μM至20 μM,或使用含有三萘啶-氮杂喹啉杂交物衍生物的抑制剂浓度为200 nM至2 μM。这使得有效地抑制RRE与Rev蛋白质的结合成为可能。